Nadja Ballin

Nadja Ballin

Auto-generated profile, based on publicly available information

Nadja Ballin

Institute of Human Genetics, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2019 in Human Mutation
Verified
Journal Article
Open access
PDF file
NBNadja Ballin
Nadja Ballin
AHAlrun Hotz
Alrun Hotz
EBEmmanuelle Bourrat
Emmanuelle Bourrat
JKJulia Küsel
Julia Küsel
VOVinzenz Oji
Vinzenz Oji
Judith FischerJudith Fischer
Judith Fischer
Autosomal recessive congenital ichthyosis (ARCI) belongs to a heterogeneous group of disorders of keratinization. To date, 10 genes have been identified to be causative for ARCI. NIPAL4 (Nipa-Like Domain-Containing 4) is the second most commonly mutated gene in ARCI. In this study, we present a large cohort of 101 families affected with ARCI carrying mutations in NIPAL4. We identified 16 novel mutations and increase the total number of pathogenic mutations in NIPAL4 to 34. Ultrastructural analysis of biopsies from six patients showed morphological abnormalities consistent with an ARCI EM type III. One patient with a homozygous splice site mutation, which leads to a loss of NIPAL4 mRNA, showed additional ultrastructural aberrations together with a more severe clinical phenotype. Our study gives insights into the frequency of mutations, a potential hot spot for mutations, and genotype–phenotype correlations.

1 December 2019 in Molecular Systems Biology
Verified
Journal Article
Open access
ÖSÖzdemirhan Serçin
Özdemirhan Serçin
SRSabine Reither
Sabine Reither
PRParis Roidos
Paris Roidos
NBNadja Ballin
Nadja Ballin
SPSpyridon Palikyras
Spyridon Palikyras
BMBalca R Mardin
Balca R Mardin
Arrayed CRISPR‐based screens emerge as a powerful alternative to pooled screens making it possible to investigate a wide range of cellular phenotypes that are typically not amenable to pooled screens. Here, we describe a solid‐phase transfection platform that enables CRISPR‐based genetic screens in arrayed format with flexible readouts. We demonstrate efficient gene knockout upon delivery of guide RNAs and Cas9/guide RNA ribonucleoprotein complexes into untransformed and cancer cell lines. In addition, we provide evidence that our platform can be easily adapted to high‐throughput screens and we use this approach to study oncogene addiction in tumor cells. Finally demonstrating that the human primary cells can also be edited using this method, we pave the way for rapid testing of potential targeted therapies.